Literature DB >> 26757789

Clinical outcomes of patients with hypothyroidism undergoing percutaneous coronary intervention.

Ming Zhang1, Jaskanwal D S Sara2, Yasushi Matsuzawa2, Hossein Gharib3, Malcolm R Bell2, Rajiv Gulati2, Lilach O Lerman4, Amir Lerman5.   

Abstract

AIMS: The aim of this study was to investigate the association between hypothyroidism and major adverse cardiovascular and cerebral events (MACCE) in patients undergoing percutaneous coronary intervention (PCI). METHODS AND
RESULTS: Two thousand four hundred and thirty patients who underwent PCI were included. Subjects were divided into two groups: hypothyroidism (n = 686) defined either as a history of hypothyroidism or thyroid-stimulating hormone (TSH) ≥5.0 mU/mL, and euthyroidism (n = 1744) defined as no history of hypothyroidism and/or 0.3 mU/mL ≤ TSH < 5.0 mU/mL. Patients with hypothyroidism were further categorized as untreated (n = 193), or those taking thyroid replacement therapy (TRT) with adequate replacement (0.3 mU/mL ≤ TSH < 5.0 mU/mL, n = 175) or inadequate replacement (TSH ≥ 5.0 mU/mL, n = 318). Adjusted hazard ratios (HRs) were calculated using Cox proportional hazards models. Median follow-up was 3.0 years (interquartile range, 0.5-7.0). After adjustment for covariates, the risk of MACCE and its constituent parts was higher in patients with hypothyroidism compared with those with euthyroidism (MACCE: HR: 1.28, P = 0.0001; myocardial infarction (MI): HR: 1.25, P = 0.037; heart failure: HR: 1.46, P = 0.004; revascularization: HR: 1.26, P = 0.0008; stroke: HR: 1.62, P = 0.04). Compared with untreated patients or those with inadequate replacement, adequately treated hypothyroid patients had a lower risk of MACCE (HR: 0.69, P = 0.005; HR: 0.78, P = 0.045), cardiac death (HR: 0.43, P = 0.008), MI (HR: 0.50, P = 0.0004; HR: 0.60, P = 0.02), and heart failure (HR: 0.50, P = 0.02; HR: 0.52, P = 0.017).
CONCLUSION: Hypothyroidism is associated with a higher incidence of MACCE compared with euthyroidism in patients undergoing PCI. Maintaining adequate control on TRT is beneficial in preventing MACCE. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2016. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Hypothyroidism; Major adverse cardiovascular and cerebral events; Percutaneous coronary intervention

Mesh:

Year:  2016        PMID: 26757789      PMCID: PMC4940453          DOI: 10.1093/eurheartj/ehv737

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  28 in total

Review 1.  The treatment of subclinical hypothyroidism is seldom necessary.

Authors:  J W Chu; L M Crapo
Journal:  J Clin Endocrinol Metab       Date:  2001-10       Impact factor: 5.958

Review 2.  Biology of the endothelium.

Authors:  T F Lüscher; M Barton
Journal:  Clin Cardiol       Date:  1997-11       Impact factor: 2.882

3.  Effects of TSH on the function of human umbilical vein endothelial cells.

Authors:  Limin Tian; Luyan Zhang; Jing Liu; Tiankang Guo; Cuixia Gao; Jing Ni
Journal:  J Mol Endocrinol       Date:  2014-03-12       Impact factor: 5.098

4.  Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression.

Authors:  E G Zouridakis; R Schwartzman; X Garcia-Moll; I D Cox; S Fredericks; D W Holt; J C Kaski
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

5.  Adequacy of thyroid hormone replacement in a general population.

Authors:  O E Okosieme; G Belludi; K Spittle; R Kadiyala; J Richards
Journal:  QJM       Date:  2010-11-24

6.  Thyroid dysfunction in patients with type 2 diabetes mellitus in Jordan.

Authors:  Abdel-Rahman M Radaideh; Mohamad K Nusier; Fawaz L Amari; Anwar E Bateiha; Mohammed S El-Khateeb; Abeer S Naser; Kamel M Ajlouni
Journal:  Saudi Med J       Date:  2004-08       Impact factor: 1.484

7.  Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study.

Authors:  Peter N Taylor; Ahmed Iqbal; Caroline Minassian; Adrian Sayers; Mohd S Draman; Rosemary Greenwood; William Hamilton; Onyebuchi Okosieme; Vijay Panicker; Sara L Thomas; Colin Dayan
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

Review 8.  Thyroid hormone and atherosclerosis.

Authors:  Toshihiro Ichiki
Journal:  Vascul Pharmacol       Date:  2009-10-04       Impact factor: 5.773

Review 9.  Mechanisms in endocrinology: Heart failure and thyroid dysfunction.

Authors:  Bernadette Biondi
Journal:  Eur J Endocrinol       Date:  2012-09-06       Impact factor: 6.664

10.  Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.

Authors:  Sigmund Silber; Per Albertsson; Francisco F Avilés; Paolo G Camici; Antonio Colombo; Christian Hamm; Erik Jørgensen; Jean Marco; Jan-Erik Nordrehaug; Witold Ruzyllo; Philip Urban; Gregg W Stone; William Wijns
Journal:  Eur Heart J       Date:  2005-03-15       Impact factor: 29.983

View more
  24 in total

1.  Association between mild thyroid dysfunction and clinical outcome in acute coronary syndrome undergoing percutaneous coronary intervention.

Authors:  Qian Cao; Yundi Jiao; Tongtong Yu; Zhaoqing Sun
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

Review 2.  Thyroid hormone receptor α1 as a novel therapeutic target for tissue repair.

Authors:  Constantinos Pantos; Iordanis Mourouzis
Journal:  Ann Transl Med       Date:  2018-06

3.  Thyroid hormones and the heart.

Authors:  Gheorghe-Andrei Dan
Journal:  Heart Fail Rev       Date:  2016-07       Impact factor: 4.214

4.  Major adverse cardiovascular and cerebral events in hypothyroid patients undergoing percutaneous coronary intervention.

Authors:  Giuseppe Pasqualetti; Valeria Calsolaro; Fabio Monzani
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

5.  Evidence and controversies regarding the screening for subclinical hypothyroidism in patients with cardiovascular disease.

Authors:  Baris Gencer; Nicolas Rodondi
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

Review 6.  Thyroid Hormone Signalling: From the Dawn of Life to the Bedside.

Authors:  Iordanis Mourouzis; Angelo Michele Lavecchia; Christodoulos Xinaris
Journal:  J Mol Evol       Date:  2019-08-27       Impact factor: 2.395

7.  Thyroid Function, Cardiovascular Risk Factors, and Incident Atherosclerotic Cardiovascular Disease: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Seth S Martin; Natalie Daya; Pamela L Lutsey; Kunihiro Matsushita; Anna Fretz; John W McEvoy; Roger S Blumenthal; Josef Coresh; Philip Greenland; Anna Kottgen; Elizabeth Selvin
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

8.  Thyroid stimulating hormone elevation as a predictor of long-term mortality in patients with acute myocardial infarction.

Authors:  Suk Min Seo; Yoon-Seok Koh; Hun-Jun Park; Dong Bin Kim; Sung Ho Her; Jong Min Lee; Chul Soo Park; Pum-Joon Kim; Hee Yeol Kim; Ki Dong Yoo; Doo Soo Jeon; Young Keun Ahn; Myung Ho Jeong; Wook Sung Chung; Ki-Bae Seung
Journal:  Clin Cardiol       Date:  2018-10-16       Impact factor: 2.882

9.  TAK1-AMPK Pathway in Macrophages Regulates Hypothyroid Atherosclerosis.

Authors:  Yunxiao Yang; Yifan Jia; Yu Ning; Wanwan Wen; Yanwen Qin; Huina Zhang; Yunhui Du; Linyi Li; Xiaolu Jiao; Yunyun Yang; Guanghui Liu; Mengling Huang; Ming Zhang
Journal:  Cardiovasc Drugs Ther       Date:  2021-06       Impact factor: 3.727

10.  Impact of Chronic Obstructive Pulmonary Disease on Long-Term Outcome in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.

Authors:  Ming Zhang; Yun-Jiu Cheng; Wei-Ping Zheng; Guang-Hui Liu; Huai-Sheng Chen; Yu Ning; Xin Zhao; Li-Xiao Su; Li-Juan Liu
Journal:  Biomed Res Int       Date:  2016-11-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.